<DOC>
	<DOCNO>NCT00039208</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving drug time day allow best drug response may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Randomized phase II trial determine best time give irinotecan combine fluorouracil , leucovorin , oxaliplatin treat patient colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine role peak delivery time tolerability irinotecan administer chronomodulated fluorouracil , leucovorin calcium , oxaliplatin first- second-line therapy patient locoregional metastatic colorectal cancer . - Determine antitumor activity regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , WHO performance status ( 0-1 v 2 ) , line treatment ( first v second ) . Patients randomize receive irinotecan 1 6 different time day . Patients receive irinotecan IV 6 hour day 1 fluorouracil IV leucovorin calcium IV 11 hour follow oxaliplatin IV 11 hour day 2-5 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 4 week disease progression every 8 week thereafter . PROJECTED ACCRUAL : A maximum 186 patient ( 31 per irinotecan administration time ) accrue study within 2 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal cancer Unresectable metastatic locoregional disease At least 1 measurable lesion outside previously irradiate area area treat physical device ( e.g. , cryotherapy , laser , thermoablation ) No prior enrollment EORTC05963 No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age : Over 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Neutrophil count great 2,000/mm^3 Platelet count least 90,000/mm^3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN No uncontrolled hypercalcemia Cardiovascular : No overt cardiac disease Pulmonary : No severe respiratory illness Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Male patient must use effective barrier contraception 6 month study No baseline diarrhea great grade I ( must less 4 stool per 24 hour ) No prior grade III IV toxicity relate irinotecan No sensory motor neuropathy functional impairment No prior hypersensitivity study drug No primary tumor except basal cell skin cancer carcinoma situ cervix No uncontrolled infectious chronic disease No psychological , familial , sociological , geographical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent prophylactic growth factor therapy Chemotherapy : At least 1 month since prior chemotherapy No prior irinotecan , fluorouracil , leucovorin calcium , oxaliplatin combination therapy Other prior therapy contain irinotecan and/or oxaliplatin allow No 1 prior chemotherapy regimen metastatic locoregional disease Adjuvant chemotherapy consider firstline therapy tumor relapse within 6 month completion therapy Endocrine therapy : No concurrent corticosteroid except emergency Radiotherapy : See Disease Characteristics Palliative radiotherapy bone lesion allow except disease progression Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>